Diphenidine Placement in Schedule I Controlled Substances
The DEA has designated diphenidine as a diphenidine schedule i controlled substance due to its high abuse potential and lack of accepted medical use. This synthetic dissociative drug is structurally related to other regulated substances and has emerged…
DEA Updates Synthetic Cannabinoid Regulation: Schedule I Placement of CUMYL-PEGACLONE
The DEA synthetic cannabinoid regulation update places CUMYL-PEGACLONE in Schedule I, reflecting its high abuse potential and no accepted medical use. This update highlights ongoing federal efforts to control emerging synthetic cannabinoids. Clinicians…
Schedules of Controlled Substances: Diphenidine Added to Schedule I
The diphenidine schedule i dea update marks its classification as a Schedule I controlled substance due to high abuse potential. This update reflects federal efforts to regulate emerging synthetic drugs. Clinicians should be aware of the diphenidine…
Schedules of Controlled Substances: Rescheduling FDA-Approved Cannabis Products and Permit Changes
The rescheduling FDA approved cannabis products implications are significant for clinical research and prescribing. This regulatory update moves certain cannabis-derived medications to Schedule III, easing permit requirements. Clinicians should…
Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I
The DEA has placed several synthetic cannabinoids into Schedule I, highlighting their high abuse potential and lack of accepted medical use. This synthetic cannabinoids schedule I classification includes 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and…
DEA Updates Synthetic Dissociative Scheduling: Diphenidine in Schedule I
The DEA synthetic dissociative scheduling update places diphenidine in Schedule I due to its high abuse potential and lack of accepted medical use. This reflects regulatory efforts to control emerging novel psychoactive substances. Clinicians should…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA emergency scheduling controlled substances update includes the temporary placement of 2-fluorodeschloroketamine in Schedule I. This reflects regulatory efforts to address emerging synthetic drugs with abuse potential. Clinicians should monitor…
Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I
The DEA has placed 3-MeO-PCP in Schedule I due to its high abuse potential and lack of accepted medical use. This regulatory action addresses emerging synthetic drugs like 3-MeO-PCP that pose public health risks. Clinicians should be aware of 3-MeO-PCP…
Schedules of Controlled Substances: Rescheduling FDA-Approved Marijuana Products to Schedule III
The DEA rescheduling cannabis products from Schedule I to Schedule III marks a pivotal regulatory change. This shift applies to FDA-approved cannabis-derived medications, easing prescribing and research barriers. Clinicians should note this change…
Schedules of Controlled Substances: DEA Update on Synthetic Cannabinoids
The DEA synthetic cannabinoids schedule I placement update designates cumyl-pegaclone as a high-risk substance with no accepted medical use. This update highlights ongoing challenges in regulating novel synthetic cannabinoids. Clinicians should be aware…